YYÜ GCRIS Basic veritabanının içerik oluşturulması ve kurulumu Research Ecosystems (https://www.researchecosystems.com) tarafından devam etmektedir. Bu süreçte gördüğünüz verilerde eksikler olabilir.

Browsing by Author "Rapisarda, A.M.C."

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Book Part
    Epidemiology and Clinical Features of Preeclampsia
    (Nova Science Publishers, Inc., 2020) Karaman, E.; Dirik, D.; Karaaslan, O.; Rapisarda, A.M.C.; Fichera, M.; Karaman, Y.
    Preeclampsia is one of most important hypertensive disorders of pregnancy. It is characterized by the new onset of hypertension and proteinuria, or of hypertension and significant end-organ dysfunction with or without proteinuria, in the last half of gestation or postpartum. It complicates about 2-8% of gestations and it is a well-known cause of maternal-perinatal morbidity and mortality. The risk factors for development of preeclampsia include genetic factors, sperm exposure, maternal smoking, pre-existing medical conditions (such as hypertension, diabetes mellitus, chronic kidney disease and anti-phospholipid syndrome), and miscellaneous ones such as nulliparity, older maternal age and obesity. The clinical presentation of preeclampsia is varied. The main symptoms are headache, visual symptoms (including blindness), epigastric pain or nausea and vomiting. Preeclampsia is classified as mild and severe based on the degree of hypertension, laboratory and clinical findings. The most severe form is the development of eclampsia and HELLP syndrome. © 2020 by Nova Science Publishers, Inc. All rights reserved.
  • Thumbnail Image
    Book Part
    Novel Therapies for Preeclampsia
    (Nova Science Publishers, Inc., 2020) Mousavi, S.N.; Rapisarda, A.M.C.; Kahramanoglu, O.; Lin, L.-T.; Karaman, E.; Arcidiacono, G.; Fichera, M.
    Preeclampsia is a serious condition that has complicated pregnancies for centuries. The angiogenic imbalance is a hallmark of preeclampsia, and angiogenic markers have proved to be effective tools for early diagnosis and prognosis of affected pregnancies. The only effective treatment for preeclampsia remains delivery, but novel therapies are being developed to ameliorate complications and prolong gestation. The aim of this chapter is to provide an updated overview of the most recent innovations and discoveries in the field of the treatment of preeclampsia. © 2020 by Nova Science Publishers, Inc. All rights reserved.